Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Medical expenditures of adult cancer survivors aged <65 years in the United States.

Short PF, Moran JR, Punekar R.

Cancer. 2011 Jun 15;117(12):2791-800. doi: 10.1002/cncr.25835. Epub 2010 Dec 23.

2.

End-of-life care for lung cancer patients in the United States and Ontario.

Warren JL, Barbera L, Bremner KE, Yabroff KR, Hoch JS, Barrett MJ, Luo J, Krahn MD.

J Natl Cancer Inst. 2011 Jun 8;103(11):853-62. doi: 10.1093/jnci/djr145. Epub 2011 May 18.

3.

Long-term employment effects of surviving cancer.

Moran JR, Short PF, Hollenbeak CS.

J Health Econ. 2011 May;30(3):505-14. doi: 10.1016/j.jhealeco.2011.02.001. Epub 2011 Mar 1.

4.

The implications of cancer survivorship for spousal employment.

Hollenbeak CS, Short PF, Moran J.

J Cancer Surviv. 2011 Sep;5(3):226-34. doi: 10.1007/s11764-011-0175-9. Epub 2011 Mar 3.

5.

Projections of the cost of cancer care in the United States: 2010-2020.

Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML.

J Natl Cancer Inst. 2011 Jan 19;103(2):117-28. doi: 10.1093/jnci/djq495. Epub 2011 Jan 12. Erratum in: J Natl Cancer Inst. 2011 Apr 20;103(8):699.

6.

Economic burden for informal caregivers of lung and colorectal cancer patients.

Van Houtven CH, Ramsey SD, Hornbrook MC, Atienza AA, van Ryn M.

Oncologist. 2010;15(8):883-93. doi: 10.1634/theoncologist.2010-0005. Epub 2010 Jul 28.

7.

Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004.

Li C, Ekwueme DU, Rim SH, Tangka FK.

Urology. 2010 Sep;76(3):528-35. doi: 10.1016/j.urology.2010.04.030. Epub 2010 Jun 22. Review.

PMID:
20573389
8.

Cancer treatment cost in the United States: has the burden shifted over time?

Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA.

Cancer. 2010 Jul 15;116(14):3477-84. doi: 10.1002/cncr.25150.

9.

Burden of illness in adult survivors of childhood cancers: findings from a population-based national sample.

Dowling E, Yabroff KR, Mariotto A, McNeel T, Zeruto C, Buckman D.

Cancer. 2010 Aug 1;116(15):3712-21. doi: 10.1002/cncr.25141.

10.

Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States.

Weaver KE, Rowland JH, Bellizzi KM, Aziz NM.

Cancer. 2010 Jul 15;116(14):3493-504. doi: 10.1002/cncr.25209.

11.

Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006.

Dinan MA, Curtis LH, Hammill BG, Patz EF Jr, Abernethy AP, Shea AM, Schulman KA.

JAMA. 2010 Apr 28;303(16):1625-31. doi: 10.1001/jama.2010.460.

PMID:
20424253
12.

Cancer's next frontier: addressing high and increasing costs.

Elkin EB, Bach PB.

JAMA. 2010 Mar 17;303(11):1086-7. doi: 10.1001/jama.2010.283. No abstract available.

13.

The value of new chemotherapeutic agents for metastatic colorectal cancer.

Howard DH, Kauh J, Lipscomb J.

Arch Intern Med. 2010 Mar 22;170(6):537-42. doi: 10.1001/archinternmed.2010.36. Epub 2010 Mar 16.

PMID:
20233802
14.

The personal financial burden of cancer for the working-aged population.

Finkelstein EA, Tangka FK, Trogdon JG, Sabatino SA, Richardson LC.

Am J Manag Care. 2009 Nov;15(11):801-6.

15.

Time costs associated with informal caregiving for cancer survivors.

Yabroff KR, Kim Y.

Cancer. 2009 Sep 15;115(18 Suppl):4362-73. doi: 10.1002/cncr.24588.

16.

Linking tumor registry and Medicaid claims to evaluate cancer care delivery.

Schrag D, Virnig BA, Warren JL.

Health Care Financ Rev. 2009 Summer;30(4):61-73.

17.

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group.

J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.

18.

Completing costs: patients' time.

Russell LB.

Med Care. 2009 Jul;47(7 Suppl 1):S89-93. doi: 10.1097/MLR.0b013e31819bc077.

PMID:
19536025
19.

Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source?

Yabroff KR, Warren JL, Banthin J, Schrag D, Mariotto A, Lawrence W, Meekins A, Topor M, Brown ML.

Med Care. 2009 Jul;47(7 Suppl 1):S64-9. doi: 10.1097/MLR.0b013e3181a23e25.

20.

Overview of methods to estimate the medical costs of cancer.

Barlow WE.

Med Care. 2009 Jul;47(7 Suppl 1):S33-6. doi: 10.1097/MLR.0b013e3181a2d847.

Items per page

Supplemental Content

Write to the Help Desk